CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate
Benzinga Newsdesk 2 months ago
NewsEarningsEarnings Misses
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of $(0.36) per share
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of $(0.36) per share from the same period last year.